So as a brief overview, soft tissue sarcomas and bone sarcomas are overall very rare cancers. There are over 100 different subtypes and overall they account for less than 1% of all adult malignancies. There’s a great need for new technology for MRD detection and treatment response monitoring for this really high unmet need population. And so we were interested in incorporating ctDNA monitoring as a method for MRD detection...
So as a brief overview, soft tissue sarcomas and bone sarcomas are overall very rare cancers. There are over 100 different subtypes and overall they account for less than 1% of all adult malignancies. There’s a great need for new technology for MRD detection and treatment response monitoring for this really high unmet need population. And so we were interested in incorporating ctDNA monitoring as a method for MRD detection. We found that there is a very high positive predictive value for ctDNA positivity. However, there are some considerations for sensitivity, for instance, for lung metastasis-only recurrence. But I think this is a really evolving area of research and really promising for transforming the care for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
